Vaximm

Focus: Vaximm is a German biotech company focused on attenuated bacterial therapy for cancer vaccines, currently advancing a single clinical-stage asset across multiple tumor indications. The company is publicly listed but operates at an early-stage development level with no approved products or commercial revenue.

Vaccines

Profile data last refreshed 3h ago · AI intelligence enriched 1w ago

Funding Stage

PUBLIC

Open Jobs

About Vaximm

AI assessmentNot Hiring

No open roles listed right now. Follow Vaximm to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

VXM01

Colorectal Cancer

Phase 1

Clinical Trials (1)

NCT02718430VXM01 Phase I Study in Patients With Metastatic Colorectal Cancer With Liver Metastasis

Phase 1

Help build intelligence for Vaximm

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage platform play: VXM01 is being explored across four distinct cancer indications (colorectal, pancreatic, glioblastoma), suggesting broad therapeutic potential for bacterial immunotherapy.
Public company status provides greater stability and equity upside than typical pre-clinical startups, with access to capital markets and potential for milestone-driven stock appreciation.
Niche scientific focus in attenuated bacterial therapy offers deep technical expertise opportunity in an under-exploited modality within immuno-oncology.

Watch Out For

Zero active job openings and no published hiring department data indicate minimal current hiring activity, suggesting limited immediate career entry points.
Pre-revenue stage with no disclosed financial data (revenue, R&D spend, cash position) creates visibility risk around runway and funding sustainability.
Early-phase pipeline (4 Phase 1 programs, 1 Phase 1/2) with no Phase 3 programs means 5+ years minimum before potential clinical validation; high attrition risk typical of single-asset biotechs.

Generated by Claude from Vaximm's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

VXM01

Stage IV Pancreatic Cancer

Phase 1

Clinical Trials (1)

NCT01486329VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer

Phase 1

VXM01

Glioblastoma

Phase 1

Clinical Trials (1)

NCT02718443VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma

Phase 1

VXM01

Recurrent Glioblastoma

Phase 1/2

Clinical Trials (1)

NCT03750071VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma

Phase 1/2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 4 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

4 pipeline

Marketed

Pipeline